Seeking Alpha

Depomed (DEPO -6.3%) slides after missing top and bottom line estimates. Sales of Gralise came...

Depomed (DEPO -6.3%) slides after missing top and bottom line estimates. Sales of Gralise came in at $6.1M as prescription growth for the shingles pain medication fell to 7% during the period. Meanwhile, sales of Zipsor fell to $3M from $4.9M in the previous two quarters. Sales of both products were affected by price increases and wholesaler inventory reductions. SA contributor and analyst Jason Napodano (who was on the CC) calls the stock "cheap" in a comprehensive rundown of the quarter. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs